Spravato: A Promising Treatment for Geriatric Depression
Managing treatment-resistant depression (TRD) in older adults can be challenging. At Philadelphia Integrative Psychiatry, Dr. Danish and his team are dedicated to providing personalized care, utilizing innovative treatments like Spravato (esketamine nasal spray) to help individuals regain control over their lives. This approach aligns with their commitment to integrating cutting-edge therapies with holistic care, ensuring patients receive comprehensive support.
A recent article titled "Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression" sheds light on the potential of Spravato in treating geriatric depression. This post-hoc analysis from the REAL-ESK study group offers valuable insights into the efficacy and safety of this treatment, reinforcing its significance in Dr. Danish's practice.
How Spravato Improves Geriatric Depression According to Recent Studies
Spravato has emerged as a viable option for older adults with TRD, demonstrating significant improvements in depressive symptoms:
Efficacy: The study reported a notable decrease in Montgomery-Åsberg Depression Rating Scale (MADRS) scores, with large effect sizes observed at both one month (Cohen's d=0.840d = 0.840) and three months (Cohen's d=1.419d = 1.419) after treatment initiation.
Response and Remission Rates: By the third month, 53.3% of participants were classified as responders (a reduction of MADRS score by at least 50%), and 33.33% achieved remission (MADRS score less than 10).
Anxiolytic Effects: Alongside reducing depressive symptoms, Spravato also significantly decreased anxiety levels, as indicated by reductions in Hamilton Anxiety Rating Scale scores.
Safety Profile and Side Effects
While Spravato shows promise, it is essential to consider its safety profile:
Common Side Effects: Dizziness (50%), dissociation (33.3%), sedation (30%), and hypertension (13.33%) were among the most frequently reported side effects.
Discontinuation Rates: About 20% of participants discontinued due to ineffectiveness or adverse effects, highlighting the need for careful patient selection and monitoring.
Getting in Touch with Dr. Danish and His Team
Whether you're struggling with geriatric depression or seeking a comprehensive evaluation, our team is here to help. Philadelphia Integrative Psychiatry stands out with its unique blend of holistic and integrative approaches, offering advanced treatments like Spravato that aren't widely available elsewhere.
For More on This Topic and Related Subjects, Check Out These Blogs by Dr. Danish:
[Leave blank for me to paste in later]
Meta Description: Discover how Spravato is transforming treatment-resistant depression in older adults at Philadelphia Integrative Psychiatry.
Sources
